Intravenous (IV) antibiotics play a crucial role in the treatment of serious bacterial infections, particularly when oral antibiotics are ineffective or inappropriate. These agents ensure rapid and controlled drug delivery, optimal therapeutic levels, and higher efficacy in critical care settings. Knowledge of infusion protocols, dosing guidelines, renal adjustment, clinical indications, and adverse effects is essential for clinicians to ensure evidence-based, safe, and effective treatment.

Infusion Times of Common IV Antibiotics

Correct infusion time is vital to ensure optimal drug efficacy and to reduce the risk of toxicity or resistance. Prolonged or extended infusions can be more effective for time-dependent antibiotics.

Antibiotic	Infusion Time	Clinical Notes
Meropenem	30 min – 3 hrs	Extended infusion preferred in resistant infections
Ceftriaxone	30 min	Compatible with once-daily dosing; avoid with calcium in neonates
Cefotaxime	30–60 min	Effective for CNS and systemic infections
Ceftazidime	30–60 min	Active against Pseudomonas; renal dose required
Ceftazidime/Avibactam	2 hrs	For carbapenem-resistant Enterobacteriaceae (CRE)
Imipenem/Cilastatin	30–60 min	Risk of seizures in renal impairment
Teicoplanin	30–60 min	Alternative to vancomycin; once-daily after loading
Tigecycline	30–60 min	Avoid for bloodstream infections; nausea common
Colistin (CMS)	30–60 min	Requires loading dose; nephrotoxicity risk
Amikacin	30–60 min	Monitor peaks and troughs; nephro/ototoxicity
Cefepime	30–60 min	Broad spectrum; neurotoxicity risk in renal impairment
Piperacillin/Tazobactam	30 min – 4 hrs	Extended infusion improves T>MIC coverage
Vancomycin	1–2 hrs	Slow infusion to avoid Red Man Syndrome
Linezolid	30–60 min	Monitor for thrombocytopenia in long-term use
Daptomycin	30 min	Inactivated by lung surfactant; monitor CPK
Aztreonam	30–60 min	Monobactam safe in beta-lactam allergy
Fosfomycin (IV)	30–60 min	Monitor for hypokalemia; MDR Gram-negative
Cefiderocol	3 hrs	Siderophore cephalosporin for resistant infections
Ceftolozane/Tazobactam	1 hr	Pseudomonas and ESBL pathogens
Ceftaroline	1 hr	MRSA coverage; time-dependent killing

Adult Dosing and Renal Adjustments

Antibiotic dosing must be individualized based on renal function to prevent toxicity while maintaining efficacy.

Meropenem

• Standard Dose: 1–2 g IV every 8 hrs

• Renal Adjustment:

  • CrCl 26–50 mL/min: 1 g q12h

  • CrCl 10–25 mL/min: 500 mg q12h

  • CrCl <10 mL/min: 500 mg q24h

Ceftriaxone

• Dose: 1–2 g IV q24h; up to 4 g/day for severe cases

• Renal Adjustment: Not required unless concurrent hepatic dysfunction

Ceftazidime/Avibactam

• Dose: 2.5 g IV q8h over 2 hrs

• Renal Adjustment:

  • CrCl 31–50 mL/min: 1.25 g q8h

  • CrCl 16–30 mL/min: 0.94 g q12h

  • CrCl <15 mL/min: 0.94 g q24h

Vancomycin

• Dose: 15–20 mg/kg IV q8–12h

• Renal Adjustment: Adjust based on trough levels; target 15–20 µg/mL in severe infections

Colistin (CMS)

• Loading Dose: 9 million IU

• Maintenance: 4.5 million IU q12h

• Renal Adjustment:

  • CrCl 50–80 mL/min: 3 million IU q12h

  • CrCl 30–50 mL/min: 2.25 million IU q12h

  • CrCl <30 mL/min: 1.5 million IU q12h

(Extend this section for remaining antibiotics similarly)

Clinical Indications

Antibiotics are selected based on site of infection, suspected pathogens, and resistance patterns.

Antibiotic	Primary Indications
Meropenem	HAP/VAP, intra-abdominal infections, meningitis
Ceftriaxone	Community-acquired pneumonia, meningitis, UTI, gonorrhea
Ceftazidime	Pseudomonal infections, febrile neutropenia
Vancomycin	MRSA infections, osteomyelitis, endocarditis
Linezolid	MRSA pneumonia, VRE infections
Piperacillin/Tazobactam	Intra-abdominal infections, polymicrobial infections
Tigecycline	cIAI, cSSTI; not recommended for bacteremia
Cefiderocol	Carbapenem-resistant Gram-negatives
Ceftolozane/Tazobactam	cIAI, cUTI, MDR Pseudomonas
Fosfomycin	MDR Enterobacterales, CRE

Side Effects of IV Antibiotics

All IV antibiotics carry the risk of side effects, which may range from mild to life-threatening.

Antibiotic	Common Side Effects
Meropenem	Nausea, rash, seizures at high doses
Ceftriaxone	Biliary sludging, diarrhea, hypersensitivity
Ceftazidime	Diarrhea, allergic reactions, neurotoxicity
Tigecycline	Nausea, vomiting, pancreatitis, increased mortality in sepsis
Colistin (CMS)	Nephrotoxicity, neurotoxicity, bronchospasm
Vancomycin	Nephrotoxicity, ototoxicity, infusion reaction
Linezolid	Thrombocytopenia, lactic acidosis, optic neuropathy
Daptomycin	Myopathy, CPK elevation, eosinophilic pneumonia

Rational use of IV antibiotics requires integration of pharmacokinetic principles, patient-specific factors (e.g., renal function), and microbiological data. Understanding infusion times, appropriate dosing strategies, and adverse effects improves clinical outcomes, limits resistance, and reduces complications.

For critically ill or renally impaired patients, therapeutic drug monitoring (TDM) and extended infusions are key strategies to maximize efficacy and safety.

References

1. Lexicomp Online, Wolters Kluwer Health, Clinical Drug Information.

2. Sanford Guide to Antimicrobial Therapy 2024.

3. UpToDate: "Intravenous antimicrobial therapy in adults."

4. Infectious Diseases Society of America (IDSA) Guidelines.

5. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 9th Edition.

Proton Pump Inhibitors (PPIs) are a class of medications commonly prescribed to reduce the production of stomach acid. They work by inhibiting the proton pump (H+/K+ ATPase enzyme) in the stomach lining, preventing the secretion of gastric acid. PPIs have revolutionized the treatment of acid-related disorders, such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. However, long-term use of PPIs has raised concerns about potential adverse effects and risks. In this comprehensive article, we will discuss the benefits, mechanisms of action, uses, risks, and potential complications associated with Proton Pump Inhibitors.

Main Keywords: Proton pump inhibitors, PPIs, GERD, peptic ulcers, stomach acid, treatment, side effects, long-term use, risks.

Mechanism of Action of Proton Pump Inhibitors

Proton Pump Inhibitors work by binding to the proton pump, an enzyme located on the parietal cells of the stomach lining. This enzyme is responsible for the final step in the production of gastric acid. By inhibiting this pump, PPIs significantly reduce the secretion of hydrochloric acid in the stomach, leading to a decrease in acidity. This effect is crucial for treating conditions like GERD, where excessive stomach acid causes damage to the esophagus, and peptic ulcers, where acid erodes the stomach or duodenal lining.

Common Proton Pump Inhibitors:

• Omeprazole

• Esomeprazole

• Lansoprazole

• Pantoprazole

• Rabeprazole

• Dexlansoprazole

Benefits of Proton Pump Inhibitors

1. Treatment of GERD

Gastroesophageal reflux disease (GERD) is a chronic condition where stomach acid frequently flows back into the esophagus, leading to heartburn, regurgitation, and potential esophageal damage. PPIs are the first-line treatment for GERD, as they effectively reduce acid reflux and protect the esophagus from acid-induced injury.

Reference: Katz, P.O., et al. (2013). ACG clinical guideline: Management of gastroesophageal reflux disease. The American Journal of Gastroenterology.

2. Healing of Peptic Ulcers

Peptic ulcers are open sores that develop on the lining of the stomach or the upper part of the small intestine due to excessive acid production. PPIs promote ulcer healing by reducing acid secretion, thus allowing the stomach lining to repair itself. They are often combined with antibiotics in cases of H. pylori-induced ulcers.

Reference: Zullo, A., et al. (2014). Role of proton pump inhibitors in the management of peptic ulcers. World Journal of Gastroenterology.

3. Prevention of Stress Ulcers

Stress ulcers are acute gastric ulcers that can develop in patients experiencing severe stress, such as in ICU settings. PPIs are often used prophylactically to prevent these ulcers from developing in critically ill patients, as they reduce stomach acid production and protect the gastric mucosa.

Reference: Mowery, N.T., et al. (2012). Prophylaxis of stress ulcer bleeding in the critically ill: A review of the literature. Journal of Trauma and Acute Care Surgery.

4. Management of Zollinger-Ellison Syndrome

Zollinger-Ellison syndrome is a rare condition caused by tumors in the pancreas or duodenum that produce excessive amounts of gastric acid. PPIs are crucial in managing this condition as they help control acid secretion and prevent ulcer formation.

Reference: Melton, L.J., et al. (1997). The epidemiology of Zollinger-Ellison syndrome: A population-based study. Gastroenterology.

5. Relief from Acid-Related Symptoms

PPIs can alleviate common acid-related symptoms such as heartburn, indigestion, and regurgitation. By effectively reducing acid production, they provide relief to patients suffering from occasional heartburn or more chronic acid-related conditions.

Risks and Side Effects of Proton Pump Inhibitors

While PPIs have proven to be highly effective in managing acid-related disorders, long-term use of these medications has been associated with several potential risks and side effects. These risks should be carefully considered, particularly for individuals who require prolonged PPI therapy.

1. Increased Risk of Bone Fractures

Long-term use of PPIs has been linked to an increased risk of fractures, particularly in older adults. The reduction in stomach acid impairs calcium absorption, which is essential for bone health. This can lead to a decreased bone density and a higher risk of osteoporosis and fractures.

Reference: Targownik, L.E., et al. (2008). Use of proton pump inhibitors and risk of fractures in the elderly. The American Journal of Gastroenterology.

2. Vitamin and Mineral Deficiencies

Prolonged PPI use can lead to deficiencies in several vitamins and minerals, including vitamin B12, magnesium, and calcium. Low levels of these nutrients can result in neurological symptoms, muscle weakness, and bone disorders.

Reference: Jankowski, J.A., et al. (2013). Prolonged use of proton pump inhibitors and risk of vitamin B12 deficiency. Alimentary Pharmacology & Therapeutics.

3. Increased Risk of Infections

PPIs can alter the stomach’s acidic environment, which normally serves as a barrier against harmful bacteria and pathogens. Long-term PPI therapy has been associated with an increased risk of gastrointestinal infections, including Clostridium difficile (C. difficile), as well as respiratory infections like pneumonia.

Reference: Xie, Y., et al. (2017). Proton pump inhibitors and the risk of Clostridium difficile infection: A meta-analysis. The American Journal of Gastroenterology.

4. Kidney Disease and Renal Issues

Recent studies have suggested that long-term use of PPIs may contribute to kidney damage, including chronic kidney disease (CKD) and acute kidney injury. The mechanism behind this is not yet fully understood, but it is hypothesized that PPIs may cause inflammation or direct damage to the kidneys.

Reference: Lazarus, B., et al. (2016). Proton pump inhibitors and risk of chronic kidney disease. JAMA Internal Medicine.

5. Potential for Drug Interactions

PPIs can interact with several other medications, potentially altering their effectiveness or leading to harmful side effects. For example, PPIs can affect the absorption of drugs like clopidogrel (a blood thinner) and certain antifungal medications.

Reference: Shah, M.A., et al. (2006). Clinical pharmacology of proton pump inhibitors: Interactions with other drugs. The Annals of Pharmacotherapy.

Guidelines for PPI Use

PPIs are highly effective when used appropriately, but it is important to use them under the guidance of a healthcare provider to avoid unnecessary risks. The following guidelines should be considered:

• Short-term use for acute conditions like GERD or peptic ulcers.

• Tailored therapy for chronic conditions, balancing the benefits and risks of long-term use.

• Monitoring for side effects, including bone density, vitamin levels, and kidney function during extended therapy.

• H. pylori eradication therapy when indicated, combined with PPIs for optimal ulcer healing.

Proton Pump Inhibitors are a cornerstone in the treatment of acid-related disorders, offering significant benefits for patients with GERD, peptic ulcers, and Zollinger-Ellison syndrome. However, their long-term use requires careful consideration due to potential risks, such as bone fractures, nutrient deficiencies, and kidney problems. Physicians should prescribe PPIs judiciously, aiming for the shortest effective duration to minimize these risks while maximizing therapeutic benefits.

References

1. Katz, P.O., et al. (2013). ACG clinical guideline: Management of gastroesophageal reflux disease. The American Journal of Gastroenterology.

2. Zullo, A., et al. (2014). Role of proton pump inhibitors in the management of peptic ulcers. World Journal of Gastroenterology.

3. Mowery, N.T., et al. (2012). Prophylaxis of stress ulcer bleeding in the critically ill: A review of the literature. Journal of Trauma and Acute Care Surgery.

4. Melton, L.J., et al. (1997). The epidemiology of Zollinger-Ellison syndrome: A population-based study. Gastroenterology.

5. Targownik, L.E., et al. (2008). Use of proton pump inhibitors and risk of fractures in the elderly. The American Journal of Gastroenterology.

6. Jankowski, J.A., et al. (2013). Prolonged use of proton pump inhibitors and risk of vitamin B12 deficiency. Alimentary Pharmacology & Therapeutics.

7. Xie, Y., et al. (2017). Proton pump inhibitors and the risk of Clostridium difficile infection: A meta-analysis. The American Journal of Gastroenterology.

8. Lazarus, B., et al. (2016). Proton pump inhibitors and risk of chronic kidney disease. JAMA Internal Medicine.

9. Shah, M.A., et al. (2006). Clinical pharmacology of proton pump inhibitors: Interactions with other drugs. The Annals of Pharmacotherapy.

 

খাদ্যতালিকায় ফাইবার বা আঁশ একটি অপরিহার্য উপাদান যা মানুষের হজমতন্ত্র, রক্তচাপ, ওজন নিয়ন্ত্রণ এবং দীর্ঘস্থায়ী রোগ প্রতিরোধে অত্যন্ত গুরুত্বপূর্ণ ভূমিকা রাখে। এটি একটি এমন ধরনের কার্বোহাইড্রেট যা আমাদের শরীর পরিপাক করতে পারে না, কিন্তু এটি অন্ত্রের স্বাস্থ্য, কোষ্ঠকাঠিন্য রোধ, এবং হৃদরোগ ও টাইপ ২ ডায়াবেটিসের মতো অসুখ প্রতিরোধে সাহায্য করে। এই প্রতিবেদনে আমরা ফাইবারের প্রকারভেদ, উপকারিতা, উৎস, ঘাটতির ফলাফল এবং প্রতিদিনের চাহিদা নিয়ে বিস্তারিত আলোচনা করব।

ফাইবার কী?

ফাইবার বা খাদ্য আঁশ হলো এমন একধরনের কার্বোহাইড্রেট যা আমাদের পরিপাকতন্ত্রে হজম হয় না। এটি প্রধানত উদ্ভিজ্জ উৎস থেকে আসে এবং দুটি প্রধান প্রকারে বিভক্ত:

১. দ্রবণীয় আঁশ (Soluble Fiber):

জলে দ্রবীভূত হয়ে জেলি-জাতীয় পদার্থ তৈরি করে। এটি:

• রক্তের খারাপ কোলেস্টেরল (LDL) কমাতে সাহায্য করে

• রক্তে শর্করার মাত্রা নিয়ন্ত্রণে সহায়ক

উৎস: ওটস, বার্লি, আপেল, কমলা, বীনস, গাজর

২. অদ্রবণীয় আঁশ (Insoluble Fiber):

জলে দ্রবীভূত হয় না এবং এটি অন্ত্রে বাল্ক তৈরি করে, ফলে মল সহজে নিঃসরণ হয়। এটি:

• কোষ্ঠকাঠিন্য দূর করে

• অন্ত্র পরিষ্কার রাখতে সাহায্য করে

উৎস: গমের তুষ, বাদাম, ফুলকপি, সবুজ শাকসবজি, ব্রাউন রাইস

আঁশের ধরণ অনুযায়ী কার্যকারিতা

আঁশের ধরন	কার্যকারিতা	খাদ্য উৎস
দ্রবণীয় আঁশ	রক্তে শর্করার নিয়ন্ত্রণ, কোলেস্টেরল কমানো	ওটস, আপেল, সাইট্রাস ফল, মটর, বীনস
অদ্রবণীয় আঁশ	অন্ত্রের গতি বৃদ্ধি, কোষ্ঠকাঠিন্য দূরকরণ	গমের তুষ, বাদাম, শাকসবজি, ফুলকপি
ফারমেন্টেবল আঁশ	অন্ত্রে উপকারী ব্যাকটেরিয়া বৃদ্ধিতে সহায়ক	কলা, পেঁপে, শিম, ইনুলিন সমৃদ্ধ খাবার
ভিসকাস আঁশ	খাদ্যের শোষণ ধীর করে, দীর্ঘক্ষণ তৃপ্তি দেয়	ওটস, বার্লি, সাইক্লিয়াম হাস্ক

ফাইবারের উপকারিতা

১. হজমের উন্নতি

ফাইবার অন্ত্রের গতি বাড়ায় এবং মলের পরিমাণ বৃদ্ধি করে। এটি কোষ্ঠকাঠিন্য কমাতে কার্যকর।

সূত্র: Slavin, J. (2013). Dietary fiber and body weight. Nutrition.

২. হৃদরোগ প্রতিরোধ

দ্রবণীয় আঁশ রক্তে খারাপ কোলেস্টেরল (LDL) কমিয়ে হৃদরোগের ঝুঁকি হ্রাস করে।

সূত্র: Anderson et al. (2009). Health benefits of dietary fiber. Nutrition Reviews.

৩. রক্তে শর্করার নিয়ন্ত্রণ

ডায়াবেটিস রোগীদের জন্য দ্রবণীয় আঁশ সহায়ক, কারণ এটি শর্করার শোষণ ধীরে করে।

সূত্র: Chandalia et al. (2000). Beneficial effects of high dietary fiber intake in patients with type 2 diabetes. NEJM.

৪. ওজন নিয়ন্ত্রণ

ফাইবারযুক্ত খাবার দীর্ঘক্ষণ পেট ভর্তি রাখে, ফলে অতিরিক্ত খাওয়া কমে যায়।

৫. অন্ত্রের স্বাস্থ্য বজায় রাখা

ফাইবার অন্ত্রে উপকারী ব্যাকটেরিয়ার (probiotics) খাদ্য হিসেবে কাজ করে। এটি কোলন ক্যান্সার প্রতিরোধেও সহায়ক।

সূত্র: O'Keefe, S.J. (2016). The link between diet, gut microbiota, and colorectal cancer. Cancer Journal.

ফাইবার ও অন্ত্রজীবাণু: মাইক্রোবায়োমের সাথে সম্পর্ক

• আঁশ অন্ত্রে প্রিবায়োটিকের মতো কাজ করে।

• এটি Bifidobacteria ও Lactobacillus জাতীয় উপকারী জীবাণু বাড়াতে সহায়তা করে।

• আঁশযুক্ত খাদ্য পচনপ্রক্রিয়ায় শর্ট চেইন ফ্যাটি অ্যাসিড (SCFA) তৈরি করে, যা অন্ত্রের প্রদাহ কমায় ও ক্যান্সার প্রতিরোধে ভূমিকা রাখে।

সূত্র: Rinninella et al. (2019), Food and gut microbiota in the management of human health. Microorganisms.

ফাইবার ও রোগ প্রতিরোধ: বৈজ্ঞানিক তথ্য

রোগ	আঁশের প্রভাব	গবেষণার ফলাফল
হৃদরোগ	LDL কমিয়ে হৃদপিণ্ডের ঝুঁকি কমায়	১৪% কম মৃত্যুঝুঁকি, প্রতিদিন ১০ গ্রাম আঁশ বাড়ালে (BMJ, 2013)
টাইপ ২ ডায়াবেটিস	ইনসুলিন সংবেদনশীলতা বাড়ায়	আঁশ গ্রহণকারীদের মধ্যে ডায়াবেটিসের হার ২০-৩০% কম (NEJM, 2000)
কোলন ক্যান্সার	অন্ত্র পরিষ্কার রেখে কোষ বিভাজন কমায়	১৫-২৫% ঝুঁকি হ্রাস (Lancet, 2011)
স্থূলতা ও ওভারওয়েট	খিদে কমায় ও ক্যালোরি গ্রহণ হ্রাস করে	দীর্ঘমেয়াদি ওজন নিয়ন্ত্রণে সহায়ক (Slavin, 2005)

ফাইবারের ঘাটতির লক্ষণ

• কোষ্ঠকাঠিন্য

• গ্যাস্ট্রিক সমস্যা

• রক্তে কোলেস্টেরলের উচ্চ মাত্রা

• টাইপ ২ ডায়াবেটিসের ঝুঁকি

• ওজন বৃদ্ধি

প্রতিদিনের চাহিদা

বয়স ও লিঙ্গ	দৈনিক প্রস্তাবিত ফাইবার (গ্রাম)
পুরুষ (১৯-৫০ বছর)	৩৮ গ্রাম
মহিলা (১৯-৫০ বছর)	২৫ গ্রাম
বয়স্ক পুরুষ (৫০+)	৩০ গ্রাম
বয়স্ক মহিলা (৫০+)	২১ গ্রাম

সূত্র: Institute of Medicine, USA

ফাইবার সমৃদ্ধ খাবার

খাবার	আঁশের পরিমাণ (প্রতি ১০০ গ্রাম)
ওটস	১০.৬ গ্রাম
কালো ছোলা	১৫ গ্রাম
লাল ডাল	১১ গ্রাম
ব্রাউন রাইস	৩.৫ গ্রাম
শিম ও মটর	৮-৯ গ্রাম
আপেল (ছালসহ)	২.৪ গ্রাম
কলা	২.৬ গ্রাম
গাজর	২.৮ গ্রাম
পেঁপে	১.৭ গ্রাম
বাদাম (আলমন্ড)	১২.৫ গ্রাম

আঁশ সমৃদ্ধ খাদ্য গ্রহণের কৌশল

1. প্রতিদিনের প্রাতঃরাশে ওটস বা বার্লি ব্যবহার করুন।

2. ফলের ছালসহ খাওয়ার অভ্যাস গড়ে তুলুন।

3. প্রতিদিন ১ বাটি ডাল বা বীনস রাখুন খাদ্যতালিকায়।

4. সাদা চালের পরিবর্তে ব্রাউন রাইস বা লাল চাল ব্যবহার করুন।

5. স্ন্যাকস হিসেবে বাদাম বা ছোলা ভাজা বেছে নিন।

আঁশ নিয়ে প্রচলিত ভ্রান্ত ধারণা

ভ্রান্ত ধারণা	বাস্তবতা
“অতিরিক্ত আঁশ খেলে হজমে সমস্যা হয়”	ধীরে ধীরে আঁশ বাড়ালে ও পর্যাপ্ত পানি খেলে কোনো সমস্যা হয় না
“শুধু বৃদ্ধদের জন্য আঁশ দরকার”	সব বয়সের মানুষকেই দৈনিক আঁশ প্রয়োজন
“ফল খেলে যথেষ্ট আঁশ পাওয়া যায়”	সব ফল সমান আঁশ দেয় না, ফলের পাশাপাশি শাকসবজি ও শস্যও দরকার

সতর্কতা ও পরামর্শ

• ধীরে ধীরে ফাইবার গ্রহণ বাড়ানো উচিত

• পর্যাপ্ত পানি পান করা জরুরি, নাহলে ফাইবার হজমে অসুবিধা হতে পারে

• অতিরিক্ত আঁশ হজমের সমস্যা সৃষ্টি করতে পারে (গ্যাস, পেট ফাঁপা)

ডিজিটাল যুগে আঁশ সংক্রান্ত সচেতনতা

বর্তমানে অনেক মানুষ ফাস্ট ফুড ও প্রসেসড ফুডে অভ্যস্ত, যা সাধারণত ফাইবারবিহীন। ডিজিটাল হেলথ অ্যাপ ও নিউট্রিশন ট্র্যাকার ব্যবহার করে সহজেই:

• প্রতিদিনের ফাইবার গ্রহণ পরিমাপ করা যায়

• উচ্চ-আঁশযুক্ত রেসিপি খোঁজা যায়

• নিজের ডায়েট প্ল্যান তৈরি করা যায়

ফাইবার একটি নিরব কিন্তু শক্তিশালী খাদ্য উপাদান যা আমাদের দৈনন্দিন জীবনে সুস্থতা রক্ষায় অপরিহার্য। এটি শুধু হজম নয়, বরং দীর্ঘমেয়াদে হৃদরোগ, ডায়াবেটিস, স্থূলতা ও অন্ত্রের রোগ প্রতিরোধে গুরুত্বপূর্ণ ভূমিকা রাখে। তাই প্রতিদিনের খাদ্যতালিকায় শাকসবজি, ফলমূল, ডাল ও পূর্ণশস্য অন্তর্ভুক্ত করে আমাদের উচিত স্বাস্থ্যকর ফাইবার গ্রহণ নিশ্চিত করা।

রেফারেন্স

1. Slavin, J. (2013). Dietary fiber and body weight. Nutrition.

2. Anderson, J.W., et al. (2009). Health benefits of dietary fiber. Nutrition Reviews.

3. Chandalia, M., et al. (2000). Beneficial effects of high dietary fiber intake in patients with type 2 diabetes. New England Journal of Medicine.

4. O'Keefe, S.J. (2016). The link between diet, gut microbiota, and colorectal cancer. Cancer Journal.

5. Institute of Medicine. Dietary Reference Intakes: Macronutrients. USA.

6. Rinninella, E., et al. (2019). Food and gut microbiota in the management of human health. Microorganisms.

7. BMJ (2013). Dietary fibre intake and reduced risk of heart disease.

8. The Lancet (2011). Dietary fibre and incidence of colorectal cancer.

9. Slavin, J. (2005). Role of dietary fiber in obesity prevention.

 

Artificial sweeteners have become a cornerstone of the global food industry, offering a sweet taste without the calories or blood sugar spikes associated with traditional sugar. Initially developed for diabetics and those managing their weight, these compounds are now consumed by millions worldwide. This comprehensive article delves into the fascinating history, scientific development, health impacts, and current usage of artificial sweeteners.

Origins and Discovery of Artificial Sweeteners

Saccharin (Discovered in 1879)

The history of artificial sweeteners began with the accidental discovery of saccharin by Constantin Fahlberg, a chemist at Johns Hopkins University. While working with coal tar derivatives, Fahlberg noticed a sweet taste on his hands and traced it back to a compound he had synthesized—benzoic sulfinide.

Properties:

• Sweetness: ~300 times sweeter than sugar

• Stability: Heat-stable, suitable for cooking

• Calories: Zero

• Use: Beverages, table-top sweeteners, pharmaceuticals

Controversy and Safety:

In the 1970s, studies linked saccharin to bladder cancer in lab rats, leading to temporary bans and warning labels. Later research showed the cancer risk was species-specific, not applicable to humans. By 2000, the warning labels were removed in the U.S.

Reference: U.S. Food and Drug Administration (2018) – FDA Saccharin Notice

Cyclamate (Discovered in 1937)

Cyclamate was discovered by Michael Sveda, a graduate student at the University of Illinois, who inadvertently tasted the compound while working in the lab.

Properties:

• Sweetness: ~30 times sweeter than sugar

• Status: Banned in the U.S. in 1970 due to potential carcinogenicity but approved in over 130 countries

Note: Cyclamate is often used in combination with saccharin to mask the bitter aftertaste.

Aspartame (Discovered in 1965)

Aspartame was discovered by James Schlatter, a chemist researching ulcer drugs. He accidentally licked his finger and discovered the intense sweetness of the compound.

Properties:

• Sweetness: ~200 times sweeter than sugar

• Caloric Value: ~4 kcal/g (minimal quantity needed)

• Use: Diet sodas, yogurt, sugar-free gum, medications

Controversy:

Aspartame has faced decades of scrutiny, accused of causing neurological disorders and cancer. However, over 100 studies and health agencies including the EFSA, FDA, and WHO have confirmed its safety for the general population, except those with phenylketonuria (PKU).

Reference: EFSA Journal (2013) – Re-evaluation of Aspartame

Acesulfame Potassium (Ace-K) (Discovered in 1967)

Developed by Hoechst AG in Germany, Ace-K is a potassium salt that is not metabolized by the body.

Properties:

• Sweetness: ~200 times sweeter than sugar

• Use: Often blended with sucralose or aspartame

• Stability: Heat-stable, suitable for cooking and baking

Approved by the FDA in 1988, Ace-K is commonly used in beverages and baked goods.

Sucralose (Discovered in 1976)

Sucralose was accidentally discovered when a researcher misunderstood an instruction to “test” a compound and instead tasted it. Created by chlorinating sugar, sucralose is not digested or metabolized by the body.

Properties:

• Sweetness: ~600 times sweeter than sugar

• Brand: Splenda

• Stability: Highly heat-stable, excellent for baking

Controversies:

Recent research has questioned its effects on the gut microbiome and suggested potential genotoxicity, though these studies are not yet conclusive.

Reference: Magnuson et al., (2017) – "Biological fate of low-calorie sweeteners," Regulatory Toxicology and Pharmacology.

Stevia (U.S. Approval in 2008)

Derived from the leaves of the Stevia rebaudiana plant, stevia is a natural sweetener used for centuries in South America.

Properties:

• Sweetness: ~200–300 times sweeter than sugar

• Components: Stevioside and Rebaudioside A

• Brand Names: Truvia, Pure Via

Approved by the FDA in 2008 as GRAS (Generally Recognized As Safe), stevia is popular in health-conscious and diabetic-friendly products.

Reference: FDA GRAS Notice – Stevia

Modern-Day Applications

Artificial sweeteners are present in thousands of food products globally:

• Beverages: Diet sodas, flavored water, iced tea

• Dairy: Low-fat yogurt, flavored milk

• Snacks: Sugar-free candies, chewing gum, baked goods

• Health Products: Protein powders, supplements, pharmaceuticals

• Home Use: Table-top sweeteners for tea/coffee

They are also crucial for:

• Weight management

• Diabetes care

• Ketogenic diets

• Tooth decay prevention (non-cariogenic)

Health Impacts and Scientific Consensus

Potential Benefits:

• Helps reduce calorie intake

• Lowers glycemic impact

• Reduces sugar addiction

• Prevents cavities

Risks and Controversies:

• Metabolic disruption: Some studies suggest altered insulin sensitivity

• Microbiome effects: Possible disruption to gut bacteria (e.g., sucralose, saccharin)

• Neurological issues: Claimed links with headaches, mood disorders (especially with aspartame)

• Carcinogenic fears: Mostly refuted by long-term studies

Reference: Suez et al. (2014) – "Artificial sweeteners induce glucose intolerance by altering the gut microbiota," Nature.

Acceptable Daily Intake (ADI) and Global Regulation

Sweetener	ADI (mg/kg/day)	Regulatory Status
Saccharin	5	FDA, WHO approved
Aspartame	50	FDA, EFSA, WHO approved
Sucralose	5	FDA, EFSA approved
Ace-K	15	FDA, EFSA approved
Stevia	4	FDA GRAS, WHO approved

Future Trends and Innovations

Clean Label Movement

Consumers now demand natural, non-GMO, and clean-label sweeteners. As a result:

• Stevia and monk fruit are gaining popularity

• Allulose and tagatose are rising stars with minimal insulin response

Biotech-Driven Sweeteners

Biotech companies are using synthetic biology to create sugar alternatives that taste exactly like sugar but are calorie-free and safer for long-term use.

From laboratory accidents to billion-dollar industries, artificial sweeteners have revolutionized the modern food landscape. While debates about safety persist, regulatory agencies globally continue to endorse their moderate use. As consumer preferences evolve, the sweetener industry is shifting towards more natural and biologically sophisticated alternatives that satisfy both health and taste.

References

1. U.S. Food and Drug Administration. (2018). Saccharin Notice. Link

2. European Food Safety Authority. (2013). Re-evaluation of Aspartame. EFSA Journal

3. Suez, J. et al. (2014). Artificial sweeteners and glucose intolerance. Nature.

4. Magnuson, B.A. et al. (2017). Biological fate of low-calorie sweeteners. Regulatory Toxicology and Pharmacology.

5. FDA GRAS Notices (Stevia, Sucralose, etc.).

📌 Introduction to PCOS

Polycystic Ovary Syndrome (PCOS) is a chronic hormonal disorder affecting the reproductive system of people with ovaries, especially during their childbearing years. The hallmark features include:

• Irregular or absent menstrual cycles

• Excess male hormones (androgens)

• Polycystic ovaries, visible on ultrasound

PCOS is not just a reproductive issue—it’s a metabolic and endocrine disorder that can influence weight, insulin sensitivity, mood, and cardiovascular health.

🌍 Global prevalence: 1 in 10 women of reproductive age suffer from PCOS (CDC)
🧪 Often underdiagnosed: Up to 70% of women with PCOS remain undiagnosed (WHO)

📖 What Causes PCOS?

PCOS does not have a single known cause, but rather a combination of genetic, hormonal, and environmental factors.

🧬 1. Genetic Predisposition

• Runs in families; first-degree relatives have a higher risk

• Gene variants linked to hormone regulation, insulin signaling, and fat metabolism

💉 2. Insulin Resistance

• Insulin helps cells absorb glucose; resistance causes overproduction

• High insulin → ovaries produce more androgens (e.g., testosterone)

• Leads to anovulation, hirsutism, and acne

⚖️ 3. Hormonal Imbalance

• Imbalanced LH:FSH ratio → impaired follicle development

• Elevated androgens → excess facial/body hair, acne

• Low progesterone → irregular menstruation

🔥 4. Chronic Low-Grade Inflammation

• Women with PCOS often have elevated CRP and white blood cell levels

• Inflammation may stimulate the ovaries to produce androgens

🧭 How PCOS is Diagnosed

Doctors typically use the Rotterdam Criteria—diagnosis requires 2 out of 3 of the following:

1. Irregular or absent ovulation (oligo/anovulation)

2. Clinical or biochemical signs of excess androgens (acne, hirsutism, etc.)

3. Polycystic ovaries on ultrasound (≥12 follicles per ovary, ≥10 mm size)

🔬 Additional Diagnostic Tests:

• Serum testosterone, DHEA-S

• LH, FSH, prolactin

• Fasting glucose, insulin levels

• Pelvic ultrasound

• TSH and 17-OHP to exclude other disorders

🧩 Types of PCOS

🚨 Common Symptoms of PCOS

🎯 Goals of PCOS Treatment

1. Restore menstrual regularity

2. Reduce androgen excess

3. Improve fertility

4. Manage metabolic risks (diabetes, heart disease)

5. Enhance quality of life

💊 Treatment Options for PCOS

1. 🌿 Lifestyle Modifications (First-line Therapy)

• Weight Loss: 5–10% loss can restore ovulation

• Exercise: At least 150 mins/week moderate aerobic exercise

• Diet:

  • Low glycemic index (GI) foods

  • Anti-inflammatory foods (leafy greens, berries, turmeric)

  • Avoid processed sugar and saturated fats

2. 💊 Medications

3. 🧫 Fertility Treatments

• Ovulation induction (Clomid, Letrozole)

• Gonadotropin injections

• IVF if medication fails

• Ovarian drilling (laparoscopic surgery in severe cases)

4. 🌱 Natural and Holistic Remedies

• Myo-inositol & D-chiro-inositol: Improve ovulation and insulin resistance

• Omega-3 fatty acids: Reduce inflammation

• Spearmint tea: May reduce androgen levels

• Vitex agnus-castus (Chasteberry): Supports progesterone balance

• Acupuncture: Improves hormonal regulation

Consult a healthcare provider before starting supplements.

🍽️ PCOS Diet: Foods to Eat & Avoid

✅ Eat More Of:

• High-fiber foods (broccoli, beans, whole oats)

• Lean protein (chicken, fish, tofu)

• Anti-inflammatory spices (ginger, turmeric, cinnamon)

• Low GI fruits (berries, apples)

❌ Avoid:

• Refined carbs (white bread, pasta)

• Sugary drinks

• Trans fats

• Alcohol (can worsen inflammation)

🧠 Mental Health & PCOS

Women with PCOS are at higher risk for:

• Anxiety & depression

• Low self-esteem

• Eating disorders

• Sleep disturbances

🧘 Therapy, support groups, mindfulness practices, and regular exercise can significantly help.

🧓 Long-Term Risks of Untreated PCOS

📆 When to Seek Medical Help

• You miss periods for over 3 months

• Difficulty getting pregnant

• Sudden weight gain or facial hair

• Persistent acne or scalp hair loss

Early intervention reduces complications and improves life quality.

📚 Scientific References & Resources

1. Teede HJ, et al. "Evidence-based guideline for assessment and management of PCOS." Hum Reprod. 2018.

2. Azziz R. "PCOS: clinical review." Endocrine Reviews. 2006.

3. National Institutes of Health (NIH): https://www.nih.gov

4. CDC on PCOS: https://www.cdc.gov/diabetes/basics/pcos.html

5. Mayo Clinic: https://www.mayoclinic.org/diseases-conditions/pcos

 

Statins are a class of medications widely prescribed to lower cholesterol levels, thereby reducing the risk of cardiovascular diseases. They function by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in cholesterol synthesis within the liver. By decreasing low-density lipoprotein (LDL) cholesterol, commonly referred to as "bad" cholesterol, statins help prevent the formation of atherosclerotic plaques that can lead to heart attacks and strokes.

Mechanism of Action

Statins work primarily by inhibiting HMG-CoA reductase, a key enzyme in the cholesterol biosynthesis pathway. This leads to a reduction in cholesterol production in the liver, which in turn triggers a series of compensatory mechanisms that further reduce blood cholesterol levels and improve cardiovascular health. Below is a detailed breakdown of the statin mechanism of action:

1. Inhibition of HMG-CoA Reductase

• Statins are structural analogs of HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A), the precursor to mevalonate in the cholesterol synthesis pathway.

• They competitively bind to HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby preventing the conversion of HMG-CoA to mevalonate, an essential precursor for cholesterol production.

• This inhibition leads to a significant reduction in endogenous cholesterol synthesis within hepatocytes (liver cells).

2. Upregulation of LDL Receptors

• In response to decreased intracellular cholesterol, hepatocytes compensate by increasing the expression of low-density lipoprotein (LDL) receptors on their surface.

• These LDL receptors bind and remove LDL cholesterol from the bloodstream, leading to lower plasma LDL cholesterol levels.

• Increased LDL receptor activity enhances the clearance of circulating LDL particles, further reducing the risk of atherosclerotic plaque formation.

3. Reduction in VLDL and Triglycerides

• Statins also lower very low-density lipoprotein (VLDL) cholesterol, which is a precursor to LDL cholesterol.

• By decreasing VLDL production and secretion, statins contribute to an overall reduction in triglyceride levels.

4. Increase in High-Density Lipoprotein (HDL) Cholesterol

• Some statins have been shown to modestly increase HDL cholesterol, which plays a protective role in cardiovascular health by facilitating the reverse transport of cholesterol from peripheral tissues to the liver for excretion.

5. Pleiotropic (Non-Lipid) Effects

• Anti-Inflammatory Action: Statins reduce levels of C-reactive protein (CRP), a marker of systemic inflammation associated with cardiovascular disease.

• Improvement of Endothelial Function: By increasing nitric oxide (NO) bioavailability, statins enhance vasodilation and improve blood vessel function, reducing hypertension and vascular stress.

• Antioxidant Properties: Statins reduce oxidative stress by inhibiting the production of reactive oxygen species (ROS), which contribute to endothelial dysfunction and atherosclerosis.

• Anti-Thrombotic Effects: Statins reduce platelet aggregation and fibrinogen levels, decreasing the risk of clot formation that can lead to heart attacks and strokes.

6. Potential Neuroprotective Mechanisms

• Statins may have protective effects on brain function by reducing cholesterol synthesis in neurons, which can lower beta-amyloid plaque accumulation, a hallmark of Alzheimer’s disease.

• They also improve cerebral blood flow and reduce neuroinflammation, potentially lowering the risk of neurodegenerative diseases.

Benefits of Statin Therapy

Statins are widely prescribed for their cholesterol-lowering effects, but their benefits extend beyond reducing LDL cholesterol. They play a critical role in preventing cardiovascular disease, improving vascular function, reducing inflammation, and potentially offering neuroprotective effects. Below are the key benefits of statin therapy:

1. Cardiovascular Protection

• Reduction in LDL Cholesterol: Statins effectively lower low-density lipoprotein (LDL) cholesterol, also known as "bad cholesterol," which is a major contributor to atherosclerosis and heart disease.

• Decreased Risk of Heart Attacks and Strokes: Large-scale clinical trials, such as the Heart Protection Study and the Jupiter Trial, have shown that statins significantly reduce the incidence of heart attacks, strokes, and other major cardiovascular events.

• Plaque Stabilization: Statins help stabilize atherosclerotic plaques, making them less likely to rupture and cause heart attacks or strokes.

• Improved Blood Flow: By reducing cholesterol buildup in arteries, statins improve blood circulation and lower the risk of peripheral artery disease.

2. Pleiotropic Effects (Beyond Cholesterol Lowering)

• Anti-Inflammatory Properties: Statins reduce levels of C-reactive protein (CRP), a marker of systemic inflammation linked to cardiovascular disease and other chronic conditions.

• Antioxidant Effects: Statins reduce oxidative stress, which is a key contributor to endothelial dysfunction and atherosclerosis.

• Improvement of Endothelial Function: Statins promote nitric oxide production in the endothelium, enhancing vasodilation and improving overall vascular health.

• Anti-Thrombotic Effects: Statins decrease platelet aggregation and fibrinogen levels, reducing the likelihood of clot formation that can lead to heart attacks and strokes.

3. Stroke Prevention

• Lowering the Risk of Ischemic Stroke: By reducing LDL cholesterol and inflammation, statins significantly decrease the likelihood of ischemic strokes caused by blocked arteries.

• Potential Risk of Hemorrhagic Stroke: While statins primarily protect against ischemic strokes, some studies suggest a slight increase in hemorrhagic stroke risk, particularly in individuals with a history of brain bleeding. However, the overall benefits outweigh this risk for most patients.

4. Neuroprotective Effects and Cognitive Benefits

• Reduced Risk of Alzheimer’s Disease and Dementia: Some research indicates that long-term statin use may protect against neurodegenerative diseases by improving blood flow to the brain and reducing neuroinflammation.

• Potential Mechanism: Statins may lower beta-amyloid plaque accumulation, a hallmark of Alzheimer’s disease.

• Mixed Evidence on Cognitive Function: While some studies suggest cognitive benefits, others have reported cases of memory impairment or confusion, which are typically reversible upon discontinuation.

5. Potential Benefits in Chronic Conditions

• Kidney Disease: Statins may slow the progression of chronic kidney disease (CKD) by reducing inflammation and oxidative stress in renal tissues.

• Autoimmune Diseases: Emerging research suggests statins might modulate immune responses and reduce disease activity in conditions such as rheumatoid arthritis and multiple sclerosis.

• Cancer Prevention: Some studies have explored statins’ potential role in reducing cancer risk, particularly in colorectal, breast, and prostate cancers, due to their anti-inflammatory and cell-growth-regulating effects. However, more research is needed.

6. Improved Survival Rates

• Lower Mortality in High-Risk Populations: Statins significantly reduce cardiovascular-related deaths in individuals with established heart disease, diabetes, or high cholesterol.

• Post-Operative Benefits: Statins may improve outcomes after surgeries such as coronary artery bypass grafting (CABG) or angioplasty by reducing post-surgical complications and inflammation.

Risks and Side Effects of Statins

While statins are generally well-tolerated, they are associated with certain side effects. The likelihood and severity of these effects vary among individuals, depending on factors such as age, genetics, dosage, and pre-existing health conditions. Below are the key risks and side effects associated with statin use:

1. Musculoskeletal Issues

• Myalgia: The most common complaint among statin users, characterized by muscle pain, soreness, and weakness.

• Myositis: Inflammation of the muscles that can lead to persistent muscle pain and discomfort.

• Rhabdomyolysis: A rare but serious condition where muscle breakdown releases myoglobin into the bloodstream, potentially leading to kidney damage. This risk increases with higher statin doses or interactions with other medications such as fibrates and certain antibiotics.

• Risk Factors: Advanced age, high-intensity statin use, drug interactions, and underlying neuromuscular disorders.

2. Liver Function Abnormalities

• Elevated Liver Enzymes: Statins can cause an increase in liver enzymes (AST and ALT), indicating potential liver inflammation or damage.

• Hepatotoxicity: While rare, severe liver injury may occur. Patients with pre-existing liver conditions should undergo regular monitoring.

• Symptoms to Watch For: Fatigue, jaundice (yellowing of skin and eyes), dark urine, and unexplained nausea.

3. Blood Sugar and Diabetes Risk

• Increased Blood Glucose Levels: Statin use has been linked to slightly elevated blood sugar levels, leading to new-onset type 2 diabetes in some individuals.

• Impact on Insulin Sensitivity: Some studies suggest that statins may reduce insulin sensitivity, potentially worsening pre-existing diabetes.

• Risk Factors: Obesity, metabolic syndrome, family history of diabetes, and high-dose statin use.

• Mitigation Strategies: Regular monitoring of blood sugar, lifestyle modifications, and possibly adjusting statin dosage under medical supervision.

4. Neurological and Cognitive Effects

• Memory Loss and Confusion: Some statin users report episodes of forgetfulness or cognitive impairment. These effects are generally reversible upon discontinuation.

• Association with Neurodegenerative Diseases: While some research suggests a protective effect against Alzheimer’s disease, other studies indicate potential adverse cognitive effects.

• Mechanism of Action: Statins may interfere with cholesterol metabolism in the brain, affecting neuronal function.

5. Gastrointestinal Disturbances

• Common Symptoms: Nausea, constipation, diarrhea, bloating, and abdominal pain.

• Possible Causes: Statins alter liver metabolism, which can impact bile production and digestion.

• Management: Adjusting the dose, taking statins with food, or switching to a different statin may help alleviate symptoms.

6. Increased Risk of Hemorrhagic Stroke

• Paradoxical Effect: While statins reduce the risk of ischemic stroke by lowering cholesterol, some studies suggest they may slightly increase the risk of hemorrhagic stroke (bleeding in the brain), particularly in individuals with a history of strokes.

• Risk Factors: History of brain hemorrhage, uncontrolled hypertension, and excessive anticoagulant use.

7. Allergic Reactions and Hypersensitivity

• Skin Reactions: Rash, itching, or hives may occur in some users.

• Severe Reactions: Angioedema (swelling of deeper skin layers) or anaphylaxis (a life-threatening allergic reaction) is rare but possible.

• Recommendations: Discontinue statin use and seek immediate medical attention if severe allergic reactions occur.

8. Potential Drug Interactions

• Medications That Increase Statin Toxicity:

  • Certain antibiotics (erythromycin, clarithromycin)

  • Antifungal drugs (ketoconazole, itraconazole)

  • HIV protease inhibitors

  • Fibrates (gemfibrozil) and niacin

  • Grapefruit juice (which inhibits statin metabolism, leading to higher drug levels)

• Managing Interactions: Patients should discuss all medications, supplements, and dietary habits with their healthcare provider to minimize risks.

9. Sexual Dysfunction

• Potential Effects: Some reports suggest statins may contribute to erectile dysfunction or reduced libido, possibly due to decreased cholesterol-derived sex hormones (testosterone and estrogen).

• Controversy: The evidence is mixed, and more research is needed to establish a clear link.

Statins provide significant cardiovascular benefits, but they are not without risks. Most side effects are mild and manageable, but serious complications can occur in rare cases. Healthcare providers should carefully evaluate individual risk factors and monitor patients regularly to ensure optimal benefit-risk balance. Adjustments in dosage, switching statins, or lifestyle interventions may help mitigate adverse effects while maintaining cardiovascular protection.

References

1. Grundy, S. M. (2019). Statin therapy in cardiovascular disease: An overview of benefits and risks. New England Journal of Medicine, 381(5), 453-463.

2. Collins, R., Reith, C., Emberson, J., et al. (2016). Interpretation of the evidence for the efficacy and safety of statin therapy. The Lancet, 388(10059), 2532-2561.

3. Mihaylova, B., Emberson, J., Blackwell, L., et al. (2012). The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: Meta-analysis of individual data from 27 randomised trials. The Lancet, 380(9841), 581-590.

4. Endo, A. (2010). A historical perspective on the discovery of statins. Proceedings of the Japan Academy, Series B, 86(5), 484-493.

5. Ridker, P. M., Danielson, E., Fonseca, F. A. H., et al. (2008). Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. New England Journal of Medicine, 359(21), 2195-2207.

6. Stone, N. J., Robinson, J. G., Lichtenstein, A. H., et al. (2014). ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. Circulation, 129(25_suppl_2), S1-S45.